NRG-GY025

Open to Accrual

Return to Protocol Table

NRG-GY025: A RANDOMIZED PHASE II TRIAL OF NIVOLUMAB AND IPILIMUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN PATIENTS WITH DEFICIENT MISMATCH REPAIR SYSTEM RECURRENT ENDOMETRIAL CARCINOMA

Principal Investigator

Haider Mahdi, MD

Status

Open to Accrual

Date Opened To Accrual

February 07 2022

Disease Site

Gynecologic [GY]

Uterine Corpus

Phase

Developmental Therapeutics

Primary Objective

To assess efficacy in terms of progression-free survival(PFS) for immunotherapy with dual immune checkpoint blockade(nivolumab/ipilimumab) vs. monotherapy (nivolumab) in patients with recurrentMMR deficient endometrial carcinoma with measurable or non-measurable(detectable) disease.

Patient Population

Measurable or non-measurable (detectable) recurrentendometrial cancer with deficient mismatch repair system

Target Accrual

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Study Memos

Safety Reports

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.